Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Rizzieri

Showing results (41-50 of 132) with videos related to

Pageof 14
Sort By:
Cancer|May 20, 2009
Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemiaDavid A Rizzieri, Jenny A O'Brien, Gloria Broadwater, et al.
Clinical Lymphoma|September 30, 2004
Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphomaJeffrey Talbot, Valerie K Ibom, David A Rizzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphomaAdam J Bass, Jon P Gockerman, Eve Hammett, et al.
The American Journal of Surgical Pathology|May 27, 2003
Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five casesJerald Z Gong, Timothy T Stenzel, Ellen R Bennett, et al.
Cancer Investigation|October 2, 2012
Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometryIvan Spasojevic, Ligia R S da Costa, Mitchell E Horwitz, et al.
British Journal of Haematology|January 17, 2014
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002David A Rizzieri, Jeffrey L Johnson, John C Byrd, et al.
British Journal of Haematology|June 19, 2012
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemiaSusan O'Brien, David A Rizzieri, Norbert Vey, et al.
Leukemia & Lymphoma|September 4, 2008
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemiaArati V Rao, Islam R Younis, Gregory J Sand, et al.
Leukemia & Lymphoma|August 1, 2002
Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemiaSteven L McCune, Jon P Gockerman, Joseph O Moore, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2017
Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine ConditioningSarah Anand, Samantha Thomas, Kelly Corbet, et al.
Pageof 14

Showing results (41-50 of 132) with videos related to

Sort By:
Pageof 14
Cancer|May 20, 2009
Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemiaDavid A Rizzieri, Jenny A O'Brien, Gloria Broadwater, et al.
Clinical Lymphoma|September 30, 2004
Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphomaJeffrey Talbot, Valerie K Ibom, David A Rizzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2002
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphomaAdam J Bass, Jon P Gockerman, Eve Hammett, et al.
The American Journal of Surgical Pathology|May 27, 2003
Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five casesJerald Z Gong, Timothy T Stenzel, Ellen R Bennett, et al.
Cancer Investigation|October 2, 2012
Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometryIvan Spasojevic, Ligia R S da Costa, Mitchell E Horwitz, et al.
British Journal of Haematology|January 17, 2014
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002David A Rizzieri, Jeffrey L Johnson, John C Byrd, et al.
British Journal of Haematology|June 19, 2012
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemiaSusan O'Brien, David A Rizzieri, Norbert Vey, et al.
Leukemia & Lymphoma|September 4, 2008
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemiaArati V Rao, Islam R Younis, Gregory J Sand, et al.
Leukemia & Lymphoma|August 1, 2002
Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemiaSteven L McCune, Jon P Gockerman, Joseph O Moore, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2017
Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine ConditioningSarah Anand, Samantha Thomas, Kelly Corbet, et al.
Pageof 14